4
Changes in Ownership
Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000097
Senior Vice President, Finance sold 10,019 shares at an average $92.43 ($926,010)
- Senior Vice President, Finance acquired 9,459 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Agarwal Arjun · Senior Vice President, Finance
Table I: Non-derivative
7 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-09-11 | Exercise or conversion : show line 1 in the form 10b5-1 | +8,000 | $12.50 | $100,000 | 23,312 | D |
| 2026-09-11 | Exercise or conversion : show line 2 in the form 10b5-1 | +1,459 | $34.39 | $50,175 | 24,771 | D |
| 2026-09-11 | Sale : show line 3 in the form 10b5-1 | −3,000 | $91.11 | $273,322 | 21,771 | D |
| 2026-09-11 | Sale : show line 4 in the form 10b5-1 | −4,051 | $92.41 | $374,367 | 17,720 | D |
| 2026-09-11 | Sale : show line 5 in the form 10b5-1 | −2,208 | $93.26 | $205,921 | 15,512 | D |
| 2026-09-11 | Sale : show line 6 in the form 10b5-1 | −200 | $94.02 | $18,803 | 15,312 | D |
| 2026-09-15 | Sale : show line 7 in the form 10b5-1 | −560 | $95.71 | $53,598 | 14,752 | D |
| Open-market sales · 10,019 sh · avg $92.43 · $926,010 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-09-11 | Exercise or conversion : show line 8 in the form 10b5-1 Employee Stock Option (right to buy) | −8,000 | 84,917 | D |
| 2026-09-11 | Exercise or conversion : show line 9 in the form 10b5-1 Employee Stock Option (right to buy) | −1,459 | 58,333 | D |
Loading xslF345X06/form4.xml…